|Bid||137.80 x 900|
|Ask||150.00 x 1000|
|Day's Range||135.01 - 138.74|
|52 Week Range||71.75 - 153.15|
|PE Ratio (TTM)||-245.29|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Incyte rose to one-month high price levels on May 18. Incyte opened higher on Thursday due to positive results from its lung cancer drug.
Jim Cramer shares his take on caller favorite stocks, including this drugmaker.
Incyte stock enjoyed a fifth consecutive day of gains Friday after its immuno-oncology drug proved robust in combination trials with Merck and Bristol.